Patents making new AIDS drugs expensive, MSF says

July 2, 2013

New potentially life-saving HIV drugs are "beyond reach" due to restrictive patents, Doctors Without Borders (MSF) said Tuesday, even though basic medication for the disease has become cheaper.

The international medical humanitarian organisation said it was good news that the price of drugs used as first- and second-line treatments had fallen by 19 and 28 percent respectively since last year.

But "salvage regimens"—drugs used as a last resort after these first two steps fail—cost 15 times as much as first-line medicines, according to an MSF statement at the International AIDS Society conference in the Malaysian capital.

"Patents keep them priced beyond reach. We need to watch carefully as newer, better medicines reach the market in the coming years, as these are the drugs that we'll quickly be needing to roll out. The price question is far from resolved," said Jennifer Cohn, medical director at MSF's Access Campaign.

According to MSF, first-line treatment—which has the highest efficacy against a low side-effect profile—can cost as little as $139 per person per year, down from $172.

It cited as the main factor in the price drop, which had also made second-line drugs available for as low as $303 per year.

But MSF said its research found the best price for a possible salvage regimen was $2,006 per year in the , while some like Armenia pay $13,213 just for one of the three or four drugs needed for a full regimen.

"Scaling up HIV treatment and sustaining people on treatment for life will depend on bringing the price of newer drugs down," said Arax Bozadjian, HIV at MSF's Access Campaign.

The group called for wider "patent opposition", claiming that a seven-year battle against Swiss Novartis, was key to falling prices of first- and second-line regimens. Novartis were finally refused a patent this April in generics-producing India.

"When patents prevent access, compulsory licences should be issued (to other drugmakers) in the interest of public health," it added.

The United Nations says 34 million people globally were living with HIV in 2011, with 2.5 million people newly infected that year alone.

In total, the global pandemic has claimed 30 million lives.

Explore further: India patent case threatens cheap drug supply: MSF

Related Stories

India patent case threatens cheap drug supply: MSF

September 5, 2011

Supply of cheap, copycat drugs for the developing world could be badly threatened if Swiss firm Novartis wins a challenge to India's patent law, medical charity MSF said on Monday.

NGOs protest Novartis' Glivec patent quest in India

February 23, 2012

Several NGOs protested Thursday at the annual meeting of Novartis against the attempt by the Swiss pharmaceutical group's India company to obtain a patent for its anti-cancer drug Glivec.

India rejects Bayer plea against cheap cancer drug (Update)

March 5, 2013

India's patent appeals office has rejected Bayer AG's plea to stop the production of a cheaper generic version of a patented cancer drug in a ruling that health groups say is an important precedent for getting inexpensive ...

Measles epidemic sweeps northern Syria

June 18, 2013

An epidemic of measles is sweeping through parts of northern Syria, with at least 7,000 people affected because the ongoing civil war has disrupted vaccination programmes, Doctors Without Borders said on Tuesday.

Recommended for you


Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (2) Jul 02, 2013
It's a money grubbing system! I am disappointed that in today's world, its all about making money from people's sicknesses and ailments, rather than restoring human health and changing lives. And can you believe they wanted to patent genes too?
not rated yet Jul 02, 2013
Yup this government is corrupt.
The CDC /IDSA receives kickbacks from Lyme disease testing companies.
Keep people sick and there pockets stay full..

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.